Current and future treatments in progressive supranuclear palsy

Area of Science:

• Neurology
• Neuroscience
• Pathology

Background:

• Progressive supranuclear palsy (PSP) is an atypical parkinsonian disorder.
• It is characterized by parkinsonism, postural instability, bulbar symptoms, supranuclear ophthalmoplegia, and executive dysfunction.
• Pathologically, PSP involves abnormal four-repeat tau aggregations in the basal ganglia and brainstem.

Purpose of the Study:

• To review current management and palliative strategies for PSP.
• To discuss challenges in diagnosis and treatment.
• To explore potential future therapeutic avenues.

Main Methods:

• Extensive literature search of studies published between 1965 and 2005.
• Review of neurotransmitter replacement and palliative strategies.
• Discussion of alternative therapies like deep brain stimulation and pallidotomy.

Main Results:

• Current management relies on neurotransmitter replacement and palliative strategies.
• Accurate and early diagnosis remains a significant challenge.
• Alternative therapies have limited documented experience.

Conclusions:

• Effective management of PSP requires symptomatic and palliative strategies.
• Improved understanding of etiopathogenesis through epidemiological studies and animal models is needed.
• Patient and caregiver education and support are vital for enhancing quality of life.